What is the Karius Test?
The Karius Test is a commercial plasma-based microbial cell-free DNA (mcfDNA) metagenomic sequencing assay that detects and quantifies pathogen DNA directly from blood samples, enabling broad-spectrum, culture-independent identification of bacteria, fungi, viruses, and parasites causing infection. 1
How It Works
The test analyzes cell-free microbial DNA circulating in plasma and reports results as molecules per microliter (molecules/μL). It uses next-generation sequencing technology to identify pathogen DNA without requiring prior suspicion of a specific organism, making it an unbiased diagnostic tool 1. The median turnaround time from sample receipt to result is 26 hours (interquartile range 25-28 hours), with 96% of samples yielding valid results 1.
What It Detects
The test can identify an extraordinarily broad range of pathogens across multiple categories:
- Bacteria: Including fastidious organisms like Mycobacterium species, Legionella, Nocardia, and Leptospira 1, 2, 3
- Fungi: Both opportunistic (Aspergillus, Pneumocystis jirovecii, Mucorales, dematiaceous fungi) and systemic dimorphic fungi 1, 4
- Viruses: DNA viruses (though clinical impact for viral detection appears limited) 1, 5
- Parasites: Including Plasmodium species causing malaria 6
In the largest reported cohort of over 15,000 patients, the test identified 701 unique microbial taxa, with 58% of reports detecting at least one pathogen 1.
Clinical Applications and Limitations
When It May Be Useful:
- Diagnostically challenging pathogens where conventional testing is limited or slow (e.g., Mycobacterium haemophilum, Leptospira santarosai) 2, 3
- Immunocompromised patients with unexplained fever or infection where multiple pathogens may coexist 4
- Mixed infections that might be missed by targeted testing 4
- Potential pre-emptive detection of bloodstream infections before symptom onset in high-risk patients (predictive sensitivity 51.9% in the 3 days before diagnosis) 7
Critical Caveats:
The real-world clinical impact is limited when used in routine practice. In a multicenter retrospective study, the Karius test led to positive clinical impact in only 7.3% of cases, negative impact in 3.7%, and no impact in 86.6% 5. This is a crucial finding that should temper enthusiasm for widespread use.
Specificity challenges exist, with a baseline predictive specificity of 82.7% that improves to 93.8% when restricting to common bloodstream pathogens and applying a DNA concentration cutoff of ≥140 molecules/μL 7. False positives are associated with gastrointestinal disturbances and recent high-dose cytarabine administration 7.
Detection does not equal causation. The test frequently identifies multiple organisms (50% of positive results show 2-8 organisms), making clinical interpretation challenging 5. Additional organisms detected beyond those identified by blood culture often show decreasing rather than increasing DNA concentrations, suggesting they may not be clinically relevant 7.
Repeated testing rarely adds value, with only 1 of 16 repeat tests in one study showing clinical impact 5.
Interpretation Pitfalls
- DNA viruses and parasites detected by the test rarely led to clinical impact in real-world use 5
- Polymicrobial results have lower predictive accuracy (adjusted OR 0.0 for sensitivity vs. monomicrobial Gram-positive infections) 7
- The test performs better diagnostically (81.3% sensitivity on day of or after bloodstream infection diagnosis) than predictively 7
Bottom Line for Clinical Use
The Karius test represents an advanced diagnostic technology that can identify unusual or fastidious pathogens when conventional testing fails, particularly in immunocompromised hosts 2, 3, 4. However, it should not replace standard microbiological methods but rather serve as a complementary tool in highly selected cases where conventional diagnostics are negative or impractical, and clinical suspicion for infection remains high. The test requires careful clinical correlation and should not be ordered routinely or repeatedly without clear indication 5.